Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

References

• Vega P, Valentín F, Cubiella J. Colorectal cancer diagnosis: Pitfalls and opportunities. World J Gastrointest Oncol. 2015;7:422–33.
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–691.
   PubMed Web of Science ®Google Scholar
• Sullivan KD, Galbraith MD, Andrysik Z, et al. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 2018;25:133–143.
   PubMed Web of Science ®Google Scholar
• Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062–1078.
   PubMed Web of Science ®Google Scholar
• Krause K, Wasner M, Reinhard W, et al. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res. 2000;28:4410–4418.
   PubMed Web of Science ®Google Scholar
• Taylor WR, Schonthal AH, Galante J. Stark GR. p130/E2F4 binds to and represses the cdc2 promoter in response to p53. J Biol Chem. 2001;276:1998–2006.
   PubMed Web of Science ®Google Scholar
• Wang H, Yan C. A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia. 2011;13:611–619.
   PubMed Web of Science ®Google Scholar
• Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang L, Hwang PM, et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 2001;7:673.
   PubMed Web of Science ®Google Scholar
• Shamas-Din A, Kale J, Leber B, et al. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol. 2013;5:a008714.
   PubMed Web of Science ®Google Scholar
• Yu J, Wang Z, Kinzler KW, et al. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A. 2003;100:1931–1936.
   PubMed Web of Science ®Google Scholar
• Huanan Wang LZ. PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer. Oncotarget. 2015;6:14385–14398.
   PubMedGoogle Scholar
• Yang S, Zhu Z, Zhang X, et al. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells. Oncotarget. 2017;8:6102–6113.
   PubMedGoogle Scholar
• Fruman DA, Cantley LC. Idelalisib – a PI3Kdelta inhibitor for B-cell cancers. N Engl J Med. 2014;370:1061–1062.
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang X, Li W. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis. Oncotarget. 2017;8:3289–3303.
   PubMedGoogle Scholar
• Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6:24.
   PubMed Web of Science ®Google Scholar
• Sun L, Huang Y, Liu Y, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-kappaB directly regulates PUMA-dependent apoptosis. Cell Death Dis. 2018;9:911.
   PubMed Web of Science ®Google Scholar
• Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18:1360–1372.
   PubMed Web of Science ®Google Scholar
• Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol Cb. 1994;4:1–7.
   PubMed Web of Science ®Google Scholar
• Rodrigues NR, Rowan A, Smith ME, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990;87:7555–7559.
   PubMed Web of Science ®Google Scholar
• Muller PAJ, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Wu MC, Chang A, et al. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a “gain of function” phenotype. Ann N Y Acad Sci. 1995;768:111–128.
   PubMedGoogle Scholar
• Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14:359.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Coillie SV, Fang JY, et al. Gain of function of mutant p53: R282W on the peak? Oncogenesis. 2016;5:e196.
   PubMed Web of Science ®Google Scholar
• Yue X, Zhang C, Zhao Y, et al. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. Genes Dev. 2017;31:1641–1654.
   PubMed Web of Science ®Google Scholar
• Schulz-Heddergott R, Stark N, Edmunds SJ, et al. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits stat3-mediated tumor growth and invasion. Cancer Cell. 2018;34:298–314 e7.
   PubMed Web of Science ®Google Scholar
• Walerych D, Lisek K, Sommaggio R, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016;18:897–909.
   PubMed Web of Science ®Google Scholar
• Weissmueller S, Manchado E, Saborowski M, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell. 2014;157:382–394.
   PubMed Web of Science ®Google Scholar
• Tan BS, Tiong KH, Choo HL, et al. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis. 2015;6:e1826.
   PubMed Web of Science ®Google Scholar
• Wiegering A, Matthes N, Mühling B, et al. Reactivating p53 and inducing tumor apoptosis (RITA) enhances the response of RITA-sensitive colorectal cancer cells to chemotherapeutic agents 5-fluorouracil and oxaliplatin. Neoplasia. 2017;19:301–309.
   PubMed Web of Science ®Google Scholar
• Raguz S, Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer. 2008;99:387–391.
   PubMed Web of Science ®Google Scholar
• Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767.
   PubMed Web of Science ®Google Scholar
• Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33:125–36 e3.
   PubMed Web of Science ®Google Scholar
• Audrey P, Ewy M, Shunsuke K, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2010;28:622–629.
   Google Scholar
• Lv Y, Zhang Y, Rubinsky B. Molecular and histological study on the effects of electrolytic electroporation on the liver. Bioelectrochemistry. 2018;125:79–89.
   PubMed Web of Science ®Google Scholar
• Wang P, Yu J, Zhang L The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage. Proc Natl Acad Sci USA. 2007;104(10):4054–4059. DOI:10.1073/pnas.0700020104. Epub 2007 Feb 28.
   Google Scholar
• Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250–1256.
   PubMed Web of Science ®Google Scholar
• Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–1238.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–310.
   PubMed Web of Science ®Google Scholar
• Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.
   PubMed Web of Science ®Google Scholar
• Punt CJA, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2016;14:235.
   PubMed Web of Science ®Google Scholar
• Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2018;15:13–30.
   PubMed Web of Science ®Google Scholar
• Alam SK, Yadav VK, Bajaj S, et al. DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53. Cell Death Differ. 2016;23:707–722.
   PubMed Web of Science ®Google Scholar
• He C, Li L, Guan X, et al. Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy. Chemotherapy. 2017;62:43–53.
   PubMed Web of Science ®Google Scholar
• Aglietti RA, Dueber EC. Recent insights into the molecular mechanisms underlying pyroptosis and gasdermin family functions. Trends Immunol. 2017;38:261–271.
   PubMed Web of Science ®Google Scholar
• Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73:1907–1916.
   PubMed Web of Science ®Google Scholar
• Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7:99–109.
   PubMed Web of Science ®Google Scholar
• Li T, Kon N, Jiang L, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149:1269–1283.
   PubMed Web of Science ®Google Scholar
• Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 2018;25:114–132.
   PubMed Web of Science ®Google Scholar
• Bykov VJN, Eriksson SE, Bianchi J, et al. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89–102.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang X, Dantas Machado AC, et al. Structure of p53 binding to the BAX response element reveals DNA unwinding and compression to accommodate base-pair insertion. Nucleic Acids Res. 2013;41:8368–8376.
   PubMed Web of Science ®Google Scholar
• Farooqi AA, de la Roche M, Djamgoz MBA, et al. Overview of the oncogenic signaling pathways in colorectal cancer: mechanistic insights. Semin Cancer Biol. 2019;58:65–79.
   PubMed Web of Science ®Google Scholar
• Campomenosi P, Monti P, Aprile A, et al. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene. 2001;20:3573–3579.
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010–1014.
   PubMed Web of Science ®Google Scholar
• Liu YC, Margolskee E, Allan JN, et al. Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis. Mod Pathol. 2019. DOI:10.1038/s41379-019-0356-z
   Web of Science ®Google Scholar
• Tanaka N, Zhao M, Tang L, et al. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1. Oncogene. 2018;37:1279–1292.
   PubMed Web of Science ®Google Scholar
• Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018;37:30.
   PubMed Web of Science ®Google Scholar
• Touil Y, Igoudjil W, Corvaisier M, et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res off J Am Assoc Cancer Res. 2014;20:837–846.
   PubMed Web of Science ®Google Scholar
• Stambolsky P, Tabach Y, Fontemaggi G, et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 2010;17:273–285.
   PubMed Web of Science ®Google Scholar
• White KA, Ruiz DG, Szpiech ZA, et al. Cancer-associated arginine-to-histidine mutations confer a gain in pH sensing to mutant proteins. Sci Signal. 2017;10(495). pii: eaam9931. DOI:10.1126/scisignal.aam9931.
   Google Scholar
• Nowak DG, Katsenelson KC, Watrud KE, et al. The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. J Cell Biol. 2019;218:1943–1957.
   PubMed Web of Science ®Google Scholar
• Brognard J, Sierecki E, Gao T, et al. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 2007;25:917–931.
   PubMed Web of Science ®Google Scholar
• Newton AC, Trotman LC. Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol. 2014;54:537–558.
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27:409–416.
   PubMed Web of Science ®Google Scholar
• Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gutgemann I, Eilers M, et al.MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227–231.
   PubMed Web of Science ®Google Scholar
• Atsaves V, Tsesmetzis N, Chioureas D, et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017;31:1633–1637.
   PubMed Web of Science ®Google Scholar